Skip to content
PICO Portalanswers from OpenAlex

Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis

PaperCitations, authors & open-access status

Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis is a paper indexed in PICO Portal from OpenAlex.

How many citations does Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis have?

PICO Portalcitation count

Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis has 171 citations in the OpenAlex counts PICO Portal stores.

When was Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis published?

PICO Portalyear

Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis has 2019 year in the PICO Portal index.

What is the open-access status of Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis?

PICO Portaloa status

Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis has green oa status in the PICO Portal index.

What is the DOI of Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis?

PICO Portaldoi

The DOI for Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis is on the source record.

What is the PMID of Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis?

PICO Portalpmid

The PMID for Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis is on the source record.

What is the OpenAlex record for Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis?

PICO Portalopenalex

The OpenAlex for Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis is on the source record.

Related on PICO Portal

470M+ articles · 14-day free trial